Term
| Sermorellin acetate (Geref) SE |
|
Definition
| increased risk of hypoglycemia so titrate dose; potential development of antibodies, joint swelling and pain |
|
|
Term
| somatomedin C (mescasermin, increlex) |
|
Definition
Acute ADR: increases glucose utilization --> hypoglycemia (49%) --? titrate dose for max effect
ADR chronic use: can develop similar SE as GH administration |
|
|
Term
| Somatostatin analogs (octreotide, lenreotide, vapreotide) |
|
Definition
| time dependent- decrease gallbladder contractility, bile secretion, avoid use with history of acute cholescystitis, biliary obstruction, cholestatsis, hepatitis, pancreatitis |
|
|
Term
| Dopaminergic agonist (bromocriptine and cabergoline)SE |
|
Definition
| nausea, dizziness, hypersomnolence, and HA. Contraindicated in hypertension and liver disease |
|
|
Term
| Pegvisomant (GH receptor antagonist) ADRs |
|
Definition
| low and acute in adults, some reports of elevated liver enzymes although no pts exhibited liver dysfunction. |
|
|
Term
| Clominphene citrate (Clomid) ADRs (if chronic administration and/or high doses) |
|
Definition
| menopausal symptoms; ovarian enlargement --> can lead to polycystic ovary disease |
|
|
Term
| ADR's associated with ADH or DDVAP Replacement (Desmopressin, Vasopressin) |
|
Definition
| increased activity of intestinal and uterine smooth muscle, water retention, inflammatino of nasal mucosas and cutaneous vasoconstriction, Significant risk for pts with CV problems (generally treated with diuretics) |
|
|
Term
| leukocytosis, lymphopenia, peptic iToxic effects of prolonged therapy with adrenal steroids |
|
Definition
| Decreased ACTH--> adrenal atrophy; growth suppression in children; general cushingoid features |
|
|
Term
|
Definition
| high incidence of hypothyroidism and life-long dependence on replacement therapy |
|
|
Term
|
Definition
| Skin rashes, mucous membrane ulcers, gastric irritation |
|
|
Term
| Finasteride and Dutasteride |
|
Definition
| Minor ADRs: impotence, decreased libido, ejaculation disorders, gynecomastia, dizziness, joint and muscle pain, rash, localized edema |
|
|
Term
| Terazosin, doxazosin, tamsulosin, alfuzosin |
|
Definition
| Contraindicated in pts requiring eye surgery; symptoms of hypotension |
|
|
Term
|
Definition
| chronic effects: decreased sexual function, increased vasomotor s/s, depression, decrease anabolic effects and increased osteoporosis |
|
|
Term
|
Definition
| common ADR: chills,fatigue, fever, back pain, nausea, joint ache, HA, cerebrovascular events |
|
|
Term
| Flutamide and Bicalutamide |
|
Definition
| Most ADRs are due to concurrent use of GnRH analogs, liver damage. Do not use with anti-coags |
|
|
Term
| PDE5 inhibitors (sidenafil, vardenafil, tadafil) |
|
Definition
| HA, flushing, GI problems, nasal congestion, sudden hearing lsos; CI with nitrates --> hypotensive crisis |
|
|
Term
|
Definition
| penile pain, hematoma, priapism, light headed fainting, nausea, HA |
|
|
Term
| Use of High Dose Testosterone to enhance athletic performance |
|
Definition
| Significant risk for BPH, prostate CA< hepatic damage, psychiatric aberrations, infertility, testicular atrophy, male pattern baldness, gynecomastia, and CAD |
|
|
Term
|
Definition
| limited use in pts with CVD can lead to increased BP and HR |
|
|
Term
|
Definition
| diarrhea, nausea, abdominal discomfort |
|
|
Term
|
Definition
| chroonic use can result in N/V, diziness/weakness. Exclude pts w/ severe CVD |
|
|
Term
|
Definition
| flatulence, cramps, diarrhea, distention, can aggravate IBD |
|
|
Term
|
Definition
| diarrhea, n/v, flatulence, indigestion, HA. Extreme: renal/hepatic dysfunction, PMH of metabolic acidosis |
|
|
Term
| Rosiglitazone, Pioglitazone |
|
Definition
| weight gain, fatigue, upper respiratory difficulties, HA, back pain, HTN |
|
|
Term
|
Definition
| N/V, HA, fatige, abdominal pain. Extreme risk: insulin and pramlintide combo use in DM-1 leads to increased incidence of hypoglycemia |
|
|
Term
|
Definition
| Nausea, dyspepsia, vomiting, HA (2nd generation decreased ADRs) CI in Type 1 DM |
|
|
Term
|
Definition
| nausea, dyspepsia, vomiting, HA. Contraindicated in Type 1 DM or severe insulin resistance |
|
|
Term
|
Definition
| N/V, dyspepsia, dizziness; CI in pts with existing or PMH of pancreatitis |
|
|
Term
|
Definition
| Symptoms of hypocalcemia; chest pain, nausea, dizziness, and diarrhea |
|
|
Term
| Ibandronate or Zoledronate |
|
Definition
| hyperacidity, dyspepsia, pain in back and extremities, diarrhea, headache, and myalgia |
|
|
Term
|
Definition
| Nausea, injection site reaction |
|
|
Term
|
Definition
| highly nephrotoxic; CI in patients with active renal disease or anuria and hepatitis |
|
|
Term
|
Definition
| hot flashes, leg cramps, and peripheral edema. Increased risk of thromboembolic events in predisposed women |
|
|
Term
|
Definition
| abdominal pain, constipation, and nausea; reduced by TID dosing |
|
|
Term
|
Definition
| Rhinitis is most common cause of discontinuation |
|
|
Term
|
Definition
| nausea, headache, dizziness, and cramps; FDA approved for severe osteoporosis only |
|
|
